EBAG9 and neoplasm: In the present study, applying an autochthonous tumor model, we found that enhanced cytolytic activity endowed Eμ-Tcl1 Ebag9–/– mice with a better clinical outcome compared with Eμ-Tcl1 Ebag9+/– mice, suggesting that immune escape can also be restored at the level of cytolytic capacity.